The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
News  >  

Patient Misconceptions About Clinical Trials Are a Common Source of Resistance, Expert Panel Says

Tony Berberabe, MPH
Published Online:2:50 PM, Mon April 8, 2019
Before a community oncology practice considers getting involved in clinical trials research, there are many factors to consider. Perhaps foremost is the fact that cancer clinical trials provide the evidence base for new advances in oncology. 

“First off, a lot of people don’t realize that a significant amount of research occurs in the community practice setting,” said Katie Goodman, director of research at Florida Cancer Specialists, during a panel discussion at the Community Oncology Alliance’s (COA’s) 2019 Community Oncology Conference.1 Conversely, poor enrollment into clinical trials can threaten to slow progress in cancer care at a time when advances can lead to new opportunities in prevention and treatment.2

Goodman explained that there are 2 types of clinical trials that her oncology practice participates in: observational trials, in which treatment adverse effects, biomarkers, and patient tissue samples are collected while the patient is undergoing treatment with an FDA-approved agent, and treatment/interventional trials in which the objective is to determine the next treatment or improve a currently available treatment. Currently, Florida Cancer Specialists has between 50 to 60 phase I clinical trials and 50 phase II/III trials ongoing.

A common misconception among patients about enrolling in clinical trials is that this is the last treatment option available, which increases their reluctance to enroll. Goodman said that is far from the case. It is important for patients and their physicians to discuss and consider clinical trial participation “very early on when discussing the full spectrum of care that the patient receives over the course of treatment,” she said. 

Before a patient enrolls in a clinical trial, the patient reviews a complex document sometimes referred to as the informed consent document, said Harsha Vyas, MD, president of the Cancer Center of Middle Georgia. Vyas noted that it is a prolonged process to get the patient initially enrolled.

“There are multiple meetings with the patient before he is enrolled. It can take days, it can take weeks. The informed consent document is a national standard,” said co-panelist Vyas. “It doesn't matter if you enroll in a large academic medical center like The University of Texas MD Anderson Cancer Center or in my rural practice in Georgia. The standards by which we need to adhere to are exactly the same.”

Goodman said that at each step of the informed consent document, the clinical research coordinator and patient’s physician should explain the clinical trial protocol, emphasizing the amount of oversight and review the protocol underwent prior to being considered for implementation in the community practice setting. 

“That oversight extends from initial enrollment, patient recruitment, treatment, and follow-up with many opportunities for the internal review board (IRB) to stop the trial at any time and review records, go over protocols, and audit any information affecting the trial,” said co-panelist Michael Diaz, MD, director of patient advocacy at Florida Cancer Specialists, and president of COA. 

“In my organization, we have an integrated support staff made up of research coordinators, nurses, and teams that manage the IRB regulatory documentation,” said Goodman. “We also have an external ethics review board providing oversight to make sure everything that we’re doing is taking into consideration the human patient,” she added. That level of oversight might be reassuring to patients who are reluctant to participate in clinical trials. 

The other patient-centered misconception that is often encountered is that the patient is going to receive a placebo, and therefore does not want to participate. Although there are trial designs that use a placebo control, Goodman emphasized that in oncology, “it would never be appropriate to not give the patient, at the very least, the standard of care. We would not give a placebo alone, without giving a treatment that is approved and appropriate for that patient.” She pointed out that in some settings though, the standard of care is monitoring the patient without any immediate treatment. 

Diaz said that he only considers enrolling a patient in a clinical trial if it is best for the patient. “I’m generally going to go with standard of care, unless the trial is an observational study where we are trying to learn and understand how the patient’s journey is while they are being treated. Some trial designs call for standard of care and patient observation, or it’s standard of care plus ‘something else.’ What we’re trying to understand, in that case, is ‘Is the something else worth adding?’” 

Darrell Keef, member of the COA Patient Advocacy Network and a patient at Florida Cancer Specialists provided his perspective on the benefit of clinical trials. He had been diagnosed in 2014 with stage IV non–small cell lung cancer that was initially treated with chemotherapy. After 3 years, his disease progressed at which point he enrolled in an immunotherapy clinical trial after confirming that he had biomarkers that could respond. 

Although resistance to clinical trial enrollment does exist, Vyas left the audience with one sobering fact. “Since 1990, there have been 1.8 million deaths in men and 825,000 deaths in women averted because of the new drugs and treatments developed from clinical research,” he said.
 
 
References:
  1. Goodman K, Diaz M, Vyas H, Keef D. Clinical trials in the community setting: how community oncology is shaping the future of cancer care. Presented at 2019 Community Alliance Conference, April 4-5, 2019. Orlando, FL.
  2. Denicoff AM, McCaskill-Stevens W, Grubbs SS, et al. The National Cancer Institute-American Society of Clinical Oncology cancer trial accrual symposium: summary and recommendations. J Oncol Pract. 2013;9(6):267-276. doi: 10.1200/JOP.2013.001119.


Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.